Zanidatamab-hrii: Revision history

15 April 2025

• curprev 00:5000:50, 15 April 2025 Parth Vikram Singh talk contribs 24,381 bytes −446 No edit summary

11 April 2025

• curprev 10:5210:52, 11 April 2025 Parth Vikram Singh talk contribs 24,827 bytes +144 No edit summary
• curprev 10:4910:49, 11 April 2025 Parth Vikram Singh talk contribs 24,683 bytes −109 No edit summary
• curprev 10:3910:39, 11 April 2025 Parth Vikram Singh talk contribs 24,792 bytes 0 No edit summary
• curprev 10:3310:33, 11 April 2025 Parth Vikram Singh talk contribs 24,792 bytes +167 No edit summary
• curprev 10:1610:16, 11 April 2025 Parth Vikram Singh talk contribs 24,625 bytes −2 No edit summary
• curprev 10:1410:14, 11 April 2025 Parth Vikram Singh talk contribs 24,627 bytes +7,693 No edit summary
• curprev 09:4709:47, 11 April 2025 Parth Vikram Singh talk contribs 16,934 bytes +1 No edit summary
• curprev 09:1109:11, 11 April 2025 Parth Vikram Singh talk contribs 16,933 bytes +3 No edit summary
• curprev 08:5308:53, 11 April 2025 Parth Vikram Singh talk contribs 16,930 bytes −2 No edit summary
• curprev 08:4708:47, 11 April 2025 Parth Vikram Singh talk contribs 16,932 bytes +1,549 No edit summary
• curprev 08:3808:38, 11 April 2025 Parth Vikram Singh talk contribs 15,383 bytes +1,239 No edit summary
• curprev 08:3108:31, 11 April 2025 Parth Vikram Singh talk contribs 14,144 bytes +6,943 No edit summary
• curprev 07:2707:27, 11 April 2025 Parth Vikram Singh talk contribs 7,201 bytes +678 No edit summary
• curprev 07:0007:00, 11 April 2025 Parth Vikram Singh talk contribs 6,523 bytes −19 No edit summary
• curprev 04:3604:36, 11 April 2025 Parth Vikram Singh talk contribs 6,542 bytes +5,060 No edit summary

10 April 2025

• curprev 19:4919:49, 10 April 2025 Parth Vikram Singh talk contribs 1,482 bytes +1,482 Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=zanidatamab-hrii |aOrAn=a |drugClass=bispecific HER2-directed antibody |indicationType=treatment |indication=ZIIHERA is a bispecific HER2-directed antibody that is FDA approved for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. |adverseReactions=*..."